Source:http://linkedlifedata.com/resource/pubmed/id/10608889
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
53
|
pubmed:dateCreated |
2000-2-8
|
pubmed:abstractText |
The heterotetrameric sarcoglycan complex, composed of alpha-, beta-, gamma-, and delta-sarcoglycans, is an important component of the dystrophin-associated glycoprotein assembly in striated muscle. Mutations in any of the four genes encoding sarcoglycans cause a deficiency in all sarcoglycans in the sarcolemma and produce one of four types of limb-girdle muscular dystrophy. A fifth widely expressed sarcoglycan, epsilon-sarcoglycan, has been recently described. epsilon-Sarcoglycan is homologous to alpha-sarcoglycan, but whether it associates with the other sarcoglycans in muscle is not known. In this study, we use wild type and alpha-sarcoglycan-deficient mice to analyze the localization and association of sarcoglycans in skeletal muscle in vivo. The amounts of beta-, gamma-, and delta-sarcoglycans are reduced in alpha-sarcoglycan mutants, whereas the amount of epsilon-sarcoglycan is unchanged. We show here that epsilon-sarcoglycan is complexed with beta-, gamma-, and delta-sarcoglycans in both wild type and alpha-sarcoglycan mutant mice. We also use C2C12 myocytes to study the temporal expression and organization of sarcoglycan complexes during muscle cell differentiation in vitro. In C2C12 cells, alpha- and epsilon-sarcoglycans form separate complexes with beta-, gamma-, and delta-sarcoglycans. Both types of complexes are expressed at the cell surface and presumed to be functional. These results suggest that epsilon-sarcoglycan serves a function similar to that of alpha-sarcoglycan and that residual beta-, gamma-, and delta-sarcoglycan seen in mutant mice and alpha-sarcoglycan-deficient patients is due to its association with epsilon-sarcoglycan.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0021-9258
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
31
|
pubmed:volume |
274
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
38171-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:10608889-Animals,
pubmed-meshheading:10608889-Base Sequence,
pubmed-meshheading:10608889-Cell Line,
pubmed-meshheading:10608889-Cell Membrane,
pubmed-meshheading:10608889-Cytoskeletal Proteins,
pubmed-meshheading:10608889-DNA Primers,
pubmed-meshheading:10608889-Gene Targeting,
pubmed-meshheading:10608889-Membrane Glycoproteins,
pubmed-meshheading:10608889-Mice,
pubmed-meshheading:10608889-Mice, Knockout,
pubmed-meshheading:10608889-Muscle, Skeletal,
pubmed-meshheading:10608889-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:10608889-Sarcoglycans
|
pubmed:year |
1999
|
pubmed:articleTitle |
Sarcoglycan isoforms in skeletal muscle.
|
pubmed:affiliation |
Burnham Institute, La Jolla, California 92037, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|